Quantcast
Last updated on April 16, 2014 at 6:49 EDT

Latest Cytopathology Stories

2013-04-12 08:25:01

SOUTH SAN FRANCISCO, Calif., April 12, 2013 /PRNewswire/ -- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced the appointment of Shelly D. Guyer as chief financial officer. "We are delighted to welcome Shelly Guyer to the Veracyte team," said Bonnie Anderson, Veracyte's cofounder and chief executive officer. "Her extensive background in the life science and finance industries will be critical as we experience...

2013-03-28 11:58:17

In women who have a potentially or mildly abnormal cervical smear, using a DNA-based test can identify those at higher risk of having precursors of cervical cancer, according to a new Cochrane systematic review. The authors found that the DNA-based test identified patients in possible need of treatment more accurately than a repeat smear test. Cervical smear ("Pap") tests are carried out to identify women who might be at high risk of developing cervical cancer. Cells collected in the smear...

2013-03-12 08:29:43

SOUTH SAN FRANCISCO, Calif., March 12, 2013 /PRNewswire/ -- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced new study findings showing that when BRAF V600E mutation testing was conducted on ambiguous thyroid nodule samples that were subsequently classified as benign by the company's Afirma Gene Expression Classifier, no BRAF-positive cases - that would suggest cancer - were found. The study appears online in the Journal of...

2013-03-08 08:23:33

SOUTH SAN FRANCISCO, Calif., March 8, 2013 /PRNewswire/ -- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced that UnitedHealthcare, one of the nation's largest private health insurers, has issued a positive medical coverage policy for the Afirma® Gene Expression Classifier for use in assessing thyroid nodule fine needle aspirate (FNA) biopsies that are indeterminate - not clearly benign or malignant following...

2013-02-15 08:23:35

SOUTH SAN FRANCISCO, Calif., Feb. 15, 2013 /PRNewswire/ -- Veracyte, Inc. today announced that a new review article published in PLOS Currents: Evidence on Genomic Tests concludes that published studies and independent assessments and reviews of the Afirma Gene Expression Classifier support the test's use to help resolve inconclusive results on thyroid nodule fine needle aspiration (FNA) samples, and thus help patients avoid unnecessary surgery as part of thyroid cancer diagnosis. The...

2013-01-07 08:30:15

SOUTH SAN FRANCISCO, Calif., Jan. 7, 2013 /PRNewswire/ -- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced that, for the first time, molecular testing is now included in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Thyroid Carcinoma. The new NCCN Guidelines indicate that, when a thyroid nodule fine needle aspiration (FNA) result is indeterminate using...

2012-11-06 08:28:16

PHOENIX, Nov. 6, 2012 /PRNewswire/ -- VisionGate, Inc., today reported that it presented new data confirming that its breakthrough Cell-CT(TM) platform for the automated analysis of three dimensional (3D) images of cells can identify disease-associated features that are not visible using 2D cytology. The data were presented this week by VisionGate founder and CEO Alan Nelson, PhD, at the 60th Annual Scientific Meeting of the American Society of Cytopathology. The Cell-CT produces 3D...

2012-10-26 07:22:26

ALBANY, New York, October 26, 2012 /PRNewswire/ -- According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com), "Cervical Cancer Diagnostic Tests (Pap Smear, Colposcopy and ECC Procedures) Market - Global Industry Analysis by Test Type and Age Group, Market Size, Share and Forecast, 2012 - 2018 [http://www.transparencymarketresearch.com/cervical-cancer-diagnostic-tests-market.html ]," the global Pap smear test market...

2012-10-22 07:30:04

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2012 /PRNewswire/ -- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced that study findings demonstrating the analytic validity of its Afirma® Gene Expression Classifier have been published online in the Journal of Clinical Endocrinology & Metabolism (JCEM) and are scheduled to appear in the December print issue. The study adds to the growing body of published data supporting the...

2012-08-29 02:25:35

SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., Aug. 29, 2012 /PRNewswire/ -- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, and Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced that the New York State Department of Health has issued a license enabling Veracyte's Afirma® Gene Expression Classifier to be offered to patients in the state. The companies also announced that Memorial Sloan-Kettering Cancer Center...